2型口服脊髓灰质炎病毒疫苗神经毒力变异株的核苷酸序列
Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine.
作者信息
Pollard S R, Dunn G, Cammack N, Minor P D, Almond J W
机构信息
Department of Microbiology, University of Reading, England.
出版信息
J Virol. 1989 Nov;63(11):4949-51. doi: 10.1128/JVI.63.11.4949-4951.1989.
Abstract
Infectious cDNAs of the Sabin type 2 poliovirus vaccine virus and a vaccine-derived neurovirulent type 2 strain (P2/117) have been cloned in Escherichia coli. Nucleotide sequence analysis revealed that P2/117 differs from the vaccine strain by just 23 point mutations. Three occur in the 5' noncoding region. The remainder result in a total of 5 coding changes located in VP1, VP4, 2B, and 3D. The likely role of these mutations in the evolution to neurovirulence is discussed.
摘要
脊髓灰质炎病毒疫苗株萨宾2型和一株疫苗衍生的2型神经毒力株（P2/117）的感染性cDNA已在大肠杆菌中克隆。核苷酸序列分析显示，P2/117与疫苗株仅存在23个点突变差异。其中3个发生在5'非编码区。其余突变导致位于VP1、VP4、2B和3D的总共5个编码变化。文中讨论了这些突变在向神经毒力进化过程中可能发挥的作用。
相似文献
1
Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine.2型口服脊髓灰质炎病毒疫苗神经毒力变异株的核苷酸序列
J Virol. 1989 Nov;63(11):4949-51. doi: 10.1128/JVI.63.11.4949-4951.1989.
2
Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine.脊髓灰质炎减毒活疫苗（Sabin 3型）减毒的遗传基础
J Virol. 1989 Mar;63(3):1338-44. doi: 10.1128/JVI.63.3.1338-1344.1989.
3
Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine.减毒活疫苗萨宾3型口服脊髓灰质炎病毒的神经毒力回复
Nucleic Acids Res. 1984 Oct 25;12(20):7787-92. doi: 10.1093/nar/12.20.7787.
4
Nucleic acid sequence of the region of the genome encoding capsid protein VP1 of neurovirulent and attenuated type 3 polioviruses.编码神经毒力型和减毒3型脊髓灰质炎病毒衣壳蛋白VP1的基因组区域的核酸序列。
Eur J Biochem. 1983 Oct 3;135(3):529-33. doi: 10.1111/j.1432-1033.1983.tb07684.x.
5
Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome.与Sabin 3型脊髓灰质炎疫苗基因组非编码区单核苷酸变化相关的神经毒力增加。
Nature. 1985;314(6011):548-50. doi: 10.1038/314548a0.
6
Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature.对在高温下选择的感染萨宾1型脊髓灰质炎病毒回复株的猴子中与神经毒力相关的突变进行定位。
J Virol. 1990 Oct;64(10):4922-9. doi: 10.1128/JVI.64.10.4922-4929.1990.
7
Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472----U.萨宾3型脊髓灰质炎病毒基因组的翻译缺陷：与衰减突变C472→U相关
Virology. 1990 Mar;175(1):103-9. doi: 10.1016/0042-6822(90)90190-3.
8
Identification of a consistent pattern of mutations in neurovirulent variants derived from the sabin vaccine strain of poliovirus type 2.2型脊髓灰质炎病毒萨宾疫苗株衍生的神经毒力变异株中一致突变模式的鉴定
J Virol. 1991 May;65(5):2707-10. doi: 10.1128/JVI.65.5.2707-2710.1991.
9
Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions.在不同细胞培养条件下生长的口服脊髓灰质炎病毒疫苗萨宾2株的遗传稳定性和突变体选择
Virology. 1995 Jun 1;209(2):366-73. doi: 10.1006/viro.1995.1268.
10
Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.人源1型脊髓灰质炎减毒活疫苗病毒的进化：从疫苗相关麻痹型脊髓灰质炎患者中分离出的毒株特征分析
J Virol. 1997 Oct;71(10):7758-68. doi: 10.1128/JVI.71.10.7758-7768.1997.
引用本文的文献
1
Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence.工程化活减脊灰疫苗以预防毒力返祖。
Cell Host Microbe. 2020 May 13;27(5):736-751.e8. doi: 10.1016/j.chom.2020.04.003. Epub 2020 Apr 23.
2
Humanized Mice for Live-Attenuated Vaccine Research: From Unmet Potential to New Promises.用于减毒活疫苗研究的人源化小鼠：从未实现的潜力到新的希望。
Vaccines (Basel). 2020 Jan 21;8(1):36. doi: 10.3390/vaccines8010036.
3
Dynamics of Evolution of Poliovirus Neutralizing Antigenic Sites and Other Capsid Functional Domains during a Large and Prolonged Outbreak.脊髓灰质炎病毒中和抗原位点和其他衣壳功能域在一次大规模和长期暴发中的进化动力学。
J Virol. 2018 Apr 13;92(9). doi: 10.1128/JVI.01949-17. Print 2018 May 1.
4
The Golgi protein ACBD3, an interactor for poliovirus protein 3A, modulates poliovirus replication.高尔基蛋白 ACBD3 是脊髓灰质炎病毒蛋白 3A 的相互作用蛋白，可调节脊髓灰质炎病毒复制。
J Virol. 2013 Oct;87(20):11031-46. doi: 10.1128/JVI.00304-13. Epub 2013 Aug 7.
5
Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).口服脊髓灰质炎疫苗的演变及其对模拟循环疫苗衍生脊髓灰质炎病毒（cVDPV）风险的启示。
Risk Anal. 2013 Apr;33(4):680-702. doi: 10.1111/risa.12022. Epub 2013 Mar 7.
6
Molecular identification and analysis of nonserotypeable human enteroviruses.非定型人类肠病毒的分子鉴定和分析。
J Clin Microbiol. 2010 Apr;48(4):1276-82. doi: 10.1128/JCM.02384-09. Epub 2010 Feb 17.
7
Estimating the extent of vaccine-derived poliovirus infection.估算疫苗衍生脊髓灰质炎病毒感染的范围。
PLoS One. 2008;3(10):e3433. doi: 10.1371/journal.pone.0003433. Epub 2008 Oct 29.
8
Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication.三种血清型基因稳定的减毒活脊髓灰质炎病毒疫苗的合理设计：与根除脊髓灰质炎的相关性
J Virol. 2006 Sep;80(17):8653-63. doi: 10.1128/JVI.00370-06.
9
Genomic analysis of recombinant sabin clinical isolates.重组萨宾临床分离株的基因组分析。
Virus Genes. 2006 Apr;32(2):203-10. doi: 10.1007/s11262-005-6877-1.
10
Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus.抗病毒药物3(2H)-异黄酮对2型脊髓灰质炎病毒分子水平的作用机制。
Antimicrob Agents Chemother. 2004 Jun;48(6):2233-43. doi: 10.1128/AAC.48.6.2233-2243.2004.
本文引用的文献
1
Persistence of immunity after administration of formalin-treated poliovirus vaccine.接种甲醛处理的脊髓灰质炎疫苗后的免疫持久性。
Lancet. 1960 Oct 1;2(7153):715-23. doi: 10.1016/s0140-6736(60)91791-8.
2
The relation between acute persisting spinal paralysis and poliomyelitis vaccine--results of a ten-year enquiry. WHO Consultative Group.急性持续性脊髓麻痹与脊髓灰质炎疫苗的关系——十年调查结果。世界卫生组织咨询小组
Bull World Health Organ. 1982;60(2):231-42.
3
Molecular cloning of the genomes of poliovirus type 3 strains by the cDNA: RNA hybrid method.通过cDNA:RNA杂交法对3型脊髓灰质炎病毒株基因组进行分子克隆
Arch Virol. 1984;81(1-2):67-78. doi: 10.1007/BF01309297.
4
Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b.神经毒性脊髓灰质炎病毒P3/Leon/37及其减毒的萨宾疫苗衍生物P3/Leon 12a1b的基因组完整核苷酸序列比较。
Proc Natl Acad Sci U S A. 1984 Mar;81(5):1539-43. doi: 10.1073/pnas.81.5.1539.
5
Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome.减毒脊髓灰质炎病毒萨宾1型毒株基因组的完整核苷酸序列。
Proc Natl Acad Sci U S A. 1982 Oct;79(19):5793-7. doi: 10.1073/pnas.79.19.5793.
6
The nucleotide sequence of poliovirus type 3 leon 12 a1b: comparison with poliovirus type 1.脊髓灰质炎病毒3型leon 12 a1b的核苷酸序列：与脊髓灰质炎病毒1型的比较。
Nucleic Acids Res. 1983 Aug 25;11(16):5629-43. doi: 10.1093/nar/11.16.5629.
7
Multiple genetic changes can occur in the oral poliovaccines upon replication in humans.
J Gen Virol. 1981 Oct;56(Pt 2):337-47. doi: 10.1099/0022-1317-56-2-337.
8
Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome.脊髓灰质炎病毒cDNA的分子克隆及病毒基因组完整核苷酸序列的测定。
Proc Natl Acad Sci U S A. 1981 Aug;78(8):4887-91. doi: 10.1073/pnas.78.8.4887.
9
Primary structure, gene organization and polypeptide expression of poliovirus RNA.脊髓灰质炎病毒RNA的一级结构、基因组织及多肽表达
Nature. 1981 Jun 18;291(5816):547-53. doi: 10.1038/291547a0.
10
Comparative biochemical studies of type 3 poliovirus.3型脊髓灰质炎病毒的比较生化研究
J Virol. 1980 Apr;34(1):73-84. doi: 10.1128/JVI.34.1.73-84.1980.
Zotero 插件